BRPI0008228B8 - composição farmacêutica contendo n-benzoil estaurosporina e agentes solubilizantes - Google Patents

composição farmacêutica contendo n-benzoil estaurosporina e agentes solubilizantes

Info

Publication number
BRPI0008228B8
BRPI0008228B8 BRPI0008228A BR0008228A BRPI0008228B8 BR PI0008228 B8 BRPI0008228 B8 BR PI0008228B8 BR PI0008228 A BRPI0008228 A BR PI0008228A BR 0008228 A BR0008228 A BR 0008228A BR PI0008228 B8 BRPI0008228 B8 BR PI0008228B8
Authority
BR
Brazil
Prior art keywords
benzoyl staurosporine
pharmaceutical composition
composition containing
solubilizing agents
benzoyl
Prior art date
Application number
BRPI0008228A
Other languages
English (en)
Portuguese (pt)
Other versions
BR0008228A (pt
BRPI0008228B1 (pt
Inventor
Haeberlin Barbara
Paul Matthews Graham
Original Assignee
Novartis Ag Novartis Sa Novartis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10847896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0008228(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag Novartis Sa Novartis Inc filed Critical Novartis Ag Novartis Sa Novartis Inc
Publication of BR0008228A publication Critical patent/BR0008228A/pt
Publication of BRPI0008228B1 publication Critical patent/BRPI0008228B1/pt
Publication of BRPI0008228B8 publication Critical patent/BRPI0008228B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0008228A 1999-02-16 2000-02-14 composição farmacêutica contendo n-benzoil estaurosporina e agentes solubilizantes BRPI0008228B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9903547.9A GB9903547D0 (en) 1999-02-16 1999-02-16 Organic compounds
PCT/EP2000/001196 WO2000048571A1 (en) 1999-02-16 2000-02-14 Spontaneously dispersible n-benzoyl staurosporine compositions

Publications (3)

Publication Number Publication Date
BR0008228A BR0008228A (pt) 2001-10-30
BRPI0008228B1 BRPI0008228B1 (pt) 2016-08-23
BRPI0008228B8 true BRPI0008228B8 (pt) 2021-05-25

Family

ID=10847896

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0008228A BRPI0008228B8 (pt) 1999-02-16 2000-02-14 composição farmacêutica contendo n-benzoil estaurosporina e agentes solubilizantes

Country Status (34)

Country Link
US (3) US20020061873A1 (cg-RX-API-DMAC10.html)
EP (1) EP1152750B1 (cg-RX-API-DMAC10.html)
JP (2) JP5057610B2 (cg-RX-API-DMAC10.html)
KR (2) KR100880859B1 (cg-RX-API-DMAC10.html)
CN (1) CN100367930C (cg-RX-API-DMAC10.html)
AR (2) AR022589A1 (cg-RX-API-DMAC10.html)
AT (1) ATE430554T1 (cg-RX-API-DMAC10.html)
AU (1) AU765776B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0008228B8 (cg-RX-API-DMAC10.html)
CA (1) CA2362277C (cg-RX-API-DMAC10.html)
CL (1) CL2009001682A1 (cg-RX-API-DMAC10.html)
CZ (1) CZ303979B6 (cg-RX-API-DMAC10.html)
DE (1) DE60042151D1 (cg-RX-API-DMAC10.html)
DK (1) DK1152750T3 (cg-RX-API-DMAC10.html)
EC (1) ECSP083351A (cg-RX-API-DMAC10.html)
ES (1) ES2326783T3 (cg-RX-API-DMAC10.html)
GB (1) GB9903547D0 (cg-RX-API-DMAC10.html)
HK (1) HK1045807B (cg-RX-API-DMAC10.html)
HU (1) HUP0105364A3 (cg-RX-API-DMAC10.html)
ID (1) ID30504A (cg-RX-API-DMAC10.html)
IL (3) IL144512A0 (cg-RX-API-DMAC10.html)
MY (1) MY128362A (cg-RX-API-DMAC10.html)
NO (1) NO331232B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ513529A (cg-RX-API-DMAC10.html)
PE (1) PE20001499A1 (cg-RX-API-DMAC10.html)
PL (1) PL198330B1 (cg-RX-API-DMAC10.html)
PT (1) PT1152750E (cg-RX-API-DMAC10.html)
RU (1) RU2266121C2 (cg-RX-API-DMAC10.html)
SI (1) SI1152750T1 (cg-RX-API-DMAC10.html)
SK (1) SK286967B6 (cg-RX-API-DMAC10.html)
TR (1) TR200102385T2 (cg-RX-API-DMAC10.html)
TW (1) TWI240636B (cg-RX-API-DMAC10.html)
WO (1) WO2000048571A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200106677B (cg-RX-API-DMAC10.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200968B1 (en) * 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US7795246B2 (en) 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
WO2002076432A2 (en) * 2001-03-26 2002-10-03 Novartis Ag Pharmaceutical composition comprising a poorly water-soluble active ingredient, a surfactant and a water-soluble polymer
AU2002342335B2 (en) 2001-05-16 2006-02-02 Novartis Ag Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
PT1441737E (pt) * 2001-10-30 2006-12-29 Dana Farber Cancer Inst Inc Derivados de estrutura como inibidores da actividade do receptor de tirosina cinase flt3
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
CN101897662B (zh) * 2002-07-23 2013-05-22 诺瓦提斯公司 包含药物、软膏基质和增溶剂/分散剂的眼用软膏剂组合物
US7842791B2 (en) 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
TWI324604B (en) * 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
GB0419159D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos
WO2008021347A2 (en) * 2006-08-16 2008-02-21 Novartis Ag Method for making solid dispersions of highly crystalline therapeutic compounds
FR2918566B1 (fr) 2007-07-11 2009-10-09 Pierre Fabre Medicament Sa Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine.
WO2009067221A2 (en) * 2007-11-20 2009-05-28 Cephalon, Inc. Microemulsion containing indolocarbazole compound and dosage forms containing the same
EP2229936B1 (en) * 2009-03-09 2015-05-06 PharmaSol GmbH Nanonized testosterone formulations for improved bioavailability
WO2011000811A2 (en) * 2009-06-30 2011-01-06 Novartis Ag Organic compounds
RU2560677C2 (ru) * 2009-12-22 2015-08-20 Лео Фарма А/С Кожная композиция, включающая аналог витамина d и смесь растворителя и поверхностно-активных веществ
JO3337B1 (ar) * 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
WO2013042069A1 (en) 2011-09-22 2013-03-28 Ariel-University Research And Development Company, Ltd. Emulsions and methods of making emulsions
RU2742650C2 (ru) * 2015-12-09 2021-02-09 Фосфейдженикс Лимитед Фармацевтический состав
US10973761B2 (en) 2015-12-09 2021-04-13 Phosphagenics Limited Pharmaceutical formulation
JP7198754B2 (ja) 2016-12-21 2023-01-04 アベーチョ バイオテクノロジー リミテッド 方法
WO2021097256A1 (en) 2019-11-14 2021-05-20 Cohbar, Inc. Cxcr4 antagonist peptides

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963367A (en) 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4735939A (en) 1987-02-27 1988-04-05 The Dow Chemical Company Insecticidal activity of staurosporine
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
DE3824034C1 (cg-RX-API-DMAC10.html) * 1988-07-15 1989-09-14 Gustav 7290 Freudenstadt De Memminger
GB2222770B (en) * 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
DE69229779T2 (de) 1991-04-19 1999-12-23 Lds Technologies, Inc. Konvertierbare mikroemulsionsverbindungen
GB9113872D0 (en) 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
US6306421B1 (en) * 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
DK0589843T3 (da) * 1992-09-25 2002-04-02 Novartis Ag Cyclosporinholdige farmaceutiske præparater
US5981568A (en) * 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
CH686761A5 (de) 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
US5639474A (en) 1993-07-01 1997-06-17 Hanmi Pharm. Ind., Ltd. Cyclosporin soft capsule composition
JPH09510182A (ja) 1993-11-17 1997-10-14 エルディーエス・テクノロジーズ・インコーポレーテッド カプセル封入されたドラッグデリバリー用透明液
GB9325395D0 (en) 1993-12-11 1994-02-16 Ciba Geigy Ag Compositions
WO1995022331A1 (en) 1994-02-18 1995-08-24 Cephalon, Inc. Aqueous indolocarbazole solutions
WO1995032975A1 (en) * 1994-06-01 1995-12-07 Ciba-Geigy Ag Indolocarbazole derivatives for sensitizing multidrug-resistant cells to antitumor agents
MY129435A (en) * 1994-10-26 2007-04-30 Novartis Ag Pharmaceutical microemulsion preconcentrates
GB2308545B (en) 1994-10-26 1999-06-02 Novartis Ag Pharmaceutical microemulsion preconcentrates
EP0711556A1 (de) * 1994-11-09 1996-05-15 Ciba-Geigy Ag Intravenöse Lösungen für ein Staurosporinderivat
EP0733372A3 (de) * 1995-03-21 1998-05-20 Ciba-Geigy Ag Pharmazeutische Formulierungsgrundlage für Nanosuspensionen
WO1998013032A1 (en) 1996-09-27 1998-04-02 Trega Biosciences, Inc. Compositions of therapeutic agents suitable for oral administration
DE19641672A1 (de) 1996-10-10 1998-04-16 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen auf der Basis von ethylenoxidfreien und propylenoxidfreien Emulgatoren zur Herstellung von Mikroemulsionsgelen
US5827522A (en) 1996-10-30 1998-10-27 Troy Corporation Microemulsion and method
NZ314060A (en) 1997-01-13 1997-08-22 Bernard Charles Sherman Pharmaceutical microemulsion preconcentrate comprising cyclosporin dissolved in a solvent system comprising hydrophobic solvent(s) and surfactant(s)
PT988046E (pt) * 1997-01-30 2004-12-31 Novartis Ag Composicoes farmaceuticas sem oleo contendo ciclosporina a
SI0999826T1 (en) 1997-07-29 2004-12-31 Pharmacia & Upjohn Company Self-emulsifying formulation for lipophilic compounds
DK0999838T3 (da) 1997-07-29 2002-07-08 Upjohn Co Selv-emulgerende formulering for lipofile forbindelser
US6346511B1 (en) 1997-09-08 2002-02-12 Panacea Biotec Limited Pharmaceutical composition comprising cyclosporin
US6979456B1 (en) * 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
GB9814527D0 (en) * 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
AR013276A1 (es) 1998-07-31 2000-12-13 Panacea Biotec Ltd Composicion de ciclosporina transparente
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions

Also Published As

Publication number Publication date
PL198330B1 (pl) 2008-06-30
AR022589A1 (es) 2002-09-04
WO2000048571A1 (en) 2000-08-24
HUP0105364A2 (hu) 2002-05-29
JP2002537242A (ja) 2002-11-05
NZ513529A (en) 2003-10-31
GB9903547D0 (en) 1999-04-07
CN100367930C (zh) 2008-02-13
US20140056974A1 (en) 2014-02-27
ATE430554T1 (de) 2009-05-15
US8722664B2 (en) 2014-05-13
IL144512A0 (en) 2002-05-23
US8575147B2 (en) 2013-11-05
SI1152750T1 (sl) 2009-10-31
DK1152750T3 (da) 2009-08-24
NO20013964D0 (no) 2001-08-15
JP5057610B2 (ja) 2012-10-24
CZ303979B6 (cs) 2013-07-31
NO20013964L (no) 2001-10-15
BR0008228A (pt) 2001-10-30
AR082579A2 (es) 2012-12-19
KR100880859B1 (ko) 2009-01-30
HK1045807B (zh) 2008-12-05
CA2362277A1 (en) 2000-08-24
HK1045807A1 (zh) 2002-12-13
KR20080064914A (ko) 2008-07-09
CA2362277C (en) 2010-03-30
KR20010093281A (ko) 2001-10-27
RU2266121C2 (ru) 2005-12-20
ECSP083351A (es) 2008-08-29
PT1152750E (pt) 2009-08-07
BRPI0008228B1 (pt) 2016-08-23
EP1152750A1 (en) 2001-11-14
AU3154200A (en) 2000-09-04
DE60042151D1 (de) 2009-06-18
PL350556A1 (en) 2002-12-16
US20020061873A1 (en) 2002-05-23
IL192666A0 (en) 2009-02-11
MY128362A (en) 2007-01-31
JP2012111763A (ja) 2012-06-14
SK286967B6 (sk) 2009-08-06
HUP0105364A3 (en) 2003-02-28
CN1339963A (zh) 2002-03-13
PE20001499A1 (es) 2001-01-12
IL144512A (en) 2011-03-31
CZ20012931A3 (cs) 2001-11-14
EP1152750B1 (en) 2009-05-06
SK11722001A3 (sk) 2001-12-03
US20080070897A1 (en) 2008-03-20
ES2326783T3 (es) 2009-10-20
AU765776B2 (en) 2003-10-02
CL2009001682A1 (es) 2010-07-23
TWI240636B (en) 2005-10-01
ZA200106677B (en) 2003-01-14
ID30504A (id) 2001-12-13
TR200102385T2 (tr) 2002-09-23
NO331232B1 (no) 2011-11-07

Similar Documents

Publication Publication Date Title
BR0008228A (pt) Composições de n-benzoil estaurosporinaespontaneamente dispersìveis
BG106906A (bg) Пуринови производни
BRPI0108435B8 (pt) formulação e uso de entecavir de baixa dose
BR0109779A (pt) Soluções moleculares hidrofìlicas dispersas de carvedilol
TR200100894T2 (tr) Aril ikameli propanolamin türevleri, imalat yöntemleri, ilaç maddeleri, kullanımları.
ATE218582T1 (de) Cyclosporinderivate, deren herstellung und pharmazeutische zusammensetzungen
TR199903053T2 (xx) Benzimidazol t�revleri.
BR0011772A (pt) Conjugado de droga-oligÈmero, composição farmacêutica, método de solubilização de uma droga em uma microemulsão, e, métodos para fornecer um conjugado de droga ativa - hidrófilo e um conjugado de droga ativa - peg a um sìtio de um indivìduo
ATE218580T1 (de) Cyclosporinderivate, deren herstellung und pharmazeutische zusammensetzungen
TR200002299T2 (tr) Epotilon kompozisyonları.
EP1708686A4 (en) GENERAL LINEAR SHELL FORM OF FENTANYL FOR ORAL USE AND METHOD OF ADMINISTRATION
BRPI0415007A (pt) método para tratar, prevenir, modificar ou administrar dor, e, composição farmacêutica
MY119181A (en) Aryl pyrimidine derivatives
BR0113331A (pt) Derivados de fenilalanina ou seus sais parmaceuticamente aceitáveis, antagonista de integrina alfa 4, agente terapêutico ou agente preventivo para doenças inflamatórias, e, composição farmacêutica
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
AP9801378A0 (en) 9-amino-3- keto erythromycin derivatives.
DE60024491D1 (de) Schnell-wirkende, gefrier-trocknete, orale, pharmazeutische formulierung für die behandlung von migräne
ATE213940T1 (de) Parenteral anzuwendende arzneizubereitung enthaltend amiodaron
MXPA04001328A (es) Productos en combinacion de derivados de 1,4-benzotiepina-1,1-dioxido con otros ingredientes activos, y su uso.
ATE359777T1 (de) Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate
DE69919179D1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
DK1280558T3 (da) Halvfast indgivelsesvehikel og farmaceutiske sammensætninger
IT1314185B1 (it) Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi
DE69716469D1 (de) Pharmazeutische zusammensetzung enthaltend ein osteogenese foerderndes mittel und ein polyethylen-glycol
EA200200922A1 (ru) Композиция, включающая камптотецин и производное пиримидина, для лечения рака

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADO DA INT. CL: A61K 9/107; A61K 31/553; A61K 9/107; A61K 31/553; A61K 47/10; A61K 47/34; A61K 47/44; A61P 9/00; A61P 9/10; A61P 25/00; A61P 29/00; A61P 31/00; A61P 35/00; A61P 43,00.

Ipc: A61K 9/107 (2009.01), A61K 31/553 (2009.01)

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM OS ARTIGOS 8O E 13 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/08/2016, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/02/2000 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 14/02/2020